VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers
VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers
Childhood cancer: The surprising scientific facts
Current and future status of cancer care in Calmette Hospital
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
The importance of providing post-treatment care to cancer survivors
Cancer Survivorship
Cancer Care in Older Adults and Special Population
The clinical impact of the Choosing Wisely project
Why tumour markers are not recommended as screening tests
ALLO-316 demonstrates encouraging anti-tumour activity for patients with advanced or metastatic ccRCC
Addition of Salmonella-IL2 to FOLFIRINOX for metastatic stage 4 pancreatic cancer nearly doubles median survival